INNOVATIVE AGENTS AND TREATMENT MODALITIES: Edited by Ahmad Awada and Steven T. RosenChallenges adopting next-generation sequencing in community oncology practiceAshbury, Fredrick D.a,b,c; Thompson, Keitha,d,e; Williams, Caseyf,g; Williams, KirstinfAuthor Information aVieCure, Denver, Colorado, USA bDepartment of Oncology, University of Calgary, Calgary, Alberta cDalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada dFaculty of Medicine, University of Alabama, Birmingham eMontgomery Cancer Center, Montgomery, Alabama fUniversity of South Dakota gAvera Cancer Institute, Sioux Falls, South Dakota, USA Correspondence to Fredrick D. Ashbury, PhD, c/o VieCure, 4949 South Syracuse Street, Suite 450, Denver, CO 80237, USA. E-mail: [email protected] Current Opinion in Oncology: September 2021 - Volume 33 - Issue 5 - p 507-512 doi: 10.1097/CCO.0000000000000764 Buy Metrics Abstract Purpose of review We are in an exhilarating time in which innovations exist to help reduce the impact of cancer for individuals, practitioners and society. Innovative tools in cancer genomics can optimize decision-making concerning appropriate drugs (alone or in combination) to cure or prolong life. The genomic characterization of tumours can also give direction to the development of novel drugs. Next-generation tumour sequencing is increasingly becoming an essential part of clinical decision-making, and, as such, will require appropriate coordination for effective adoption and delivery. Recent findings There are several challenges that will need to be addressed if we are to facilitate cancer genomics as part of routine community oncology practice. Recent research into this novel testing paradigm has demonstrated the barriers are at the individual level, while others are at the institution and societal levels. Summary This article, based on the authors’ experience in community oncology practice and summary of literature, describes these challenges so strategies can be developed to address these challenges to improve patient outcomes. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.